REGULATORY

• MHLW Streamlines Lot Release Procedures for Vaccines, Blood Products
  April 3, 2026

• MHLW Allows Outer Packaging Labeling for Regenerative Medicine Products
  April 3, 2026

• MHLW’s Drug Supply Monitoring System Now Up and Running
  April 3, 2026

• MHLW Sets Up Contact Point on Medical Supply Risks Tied to Iran War
  April 3, 2026

• LDP, Ishin Call for Proper Valuation in CEA Scheme at Reform Talks
  April 3, 2026

• MHLW Revises Biological Raw Material Rules, Clarifies Donor Testing Flexibility
  April 2, 2026

• Japan Officially Eases Trial Recruitment Rules; Industry Welcomes Move
  April 1, 2026

• MHLW Updates Q&A on Use of Registry Data in Drug Applications
  April 1, 2026

• Japan Panel Designates Two Ebola Therapies for Early Approval Pathway
  April 1, 2026

• MHLW, METI Launch Joint Task Force to Safeguard Medical Supply Chains
  April 1, 2026

• Japan Urges Priority Supply of Petroleum-Based Materials for Medical Devices
  March 31, 2026

• Japan’s New HIV Cases Hit 20-Year Low in 2025
  March 30, 2026

• MHLW Launches Genomic Medicine Body GeMJ
  March 30, 2026

• TNF Inhibitors, Cancer Drugs Flagged in PMDA Risk Review
  March 30, 2026

• Japan Ranks 9th Among 10 in AI Analysis of EFPIA Pharma Strategy Report
  March 27, 2026

• MHLW Says Trial Recruitment Info Not Deemed Advertising Under PMD Act
  March 27, 2026

• AMED Warns Projects without Japan Return May Miss Startup Funding
  March 26, 2026

• Japan Cabinet Approves National MCM Strategy to Boost Pandemic Response
  March 25, 2026

• Pharma Urges Govt Support as Iran War Shows Early Impact on Supply Chains
  March 25, 2026

• Japan Panel Slams MHLW’s 80% Single-IRB Target as Too Low
  March 24, 2026

ページ

• « 先頭
• ‹ Prev
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »